US-based biopharmaceutical company Incyte Corporation has entered a distribution agreement for the commercialisation of its drug named Iclusig (ponatinib) in Greece with GENESIS Pharma.

The agreement was signed by Incyte’s subsidiary Incyte Biosciences International Sarl and makes GENESIS Pharma responsible for sales and marketing, medical affairs, and regulatory and reimbursement support for the drug in Greece.

Orexigen Therapeutics Ireland, the Irish subsidiary of biopharmaceutical company, Orexigen Therapeutics, has signed a distribution agreement with Valeant Pharmaceuticals International for the former’s Contrave (naltrexone HCl / bupropion HCl extended release) tablets in Australia and New Zealand.

Valeant Pharmaceutical will obtain regulatory approvals and commercialise the drug, whereas Orexigen will supply the drug to Valeant.

"Valeant Pharmaceutical will obtain regulatory approvals and commercialise the drug, whereas Orexigen will supply the drug to Valeant."

The drug sale to Valeant will include transfer prices, as well as sales-based milestone payments.

Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation has signed a joint venture (JV) agreement with Research Foundation for Microbial Diseases of Osaka University (BIKEN Foundation) to set up a vaccine manufacturing base in Japan by combining the former’s production systems with the latter’s manufacturing technologies.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The former will own a 33.4% stake in the JV, which will be operational from September 2017, while the remaining will be owned by BIKEN Foundation.

A 5% stake has been purchased in the US-based monoclonal antibody-based therapeutics developer, MacroGenics, by Mirae Asset Global Investments.

The investment company purchased 448,923 shares in the pharmaceutical company as part of the transaction.